Abstract
Children and adolescents initiating use of a selective serotonin reuptake inhibitor (SSRI) antidepressant are at a slightly increased risk of developing type 2 diabetes, a cohort study has concluded. The study examined outcomes for both publicly and privately insured individuals, with type 2 diabetes risk found to be higher in the publicly insured group.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
